ETOPOPHOS

This brand name is authorized in United States. It is also authorized in Australia, Estonia, France, New Zealand, UK.

Active ingredients

The drug ETOPOPHOS contains one active pharmaceutical ingredient (API):

1	Etoposide UNII 528XYJ8L1N - ETOPOSIDE PHOSPHATE
	The main effect of etoposide appears to be at the late S and early G2 portion of the cell cycle in mammalian cells. The predominant macromolecular effect of etoposide seems to be the rupture of the double strand by an interaction with DNA-topoisomerase II or by the formation of free radicals. Etoposide has been shown to cause metaphase arrest in chick fibroblasts.
	Read more about Etoposide

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ETOPOPHOS Powder for solution for injection	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01CB01	Etoposide	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01C Plant alkaloids and other natural products → L01CB Podophyllotoxin derivatives
Discover more medicines within L01CB01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	4428C, 7237X
EE	Ravimiamet	1810202, 1852488
FR	Base de données publique des médicaments	65619363
GB	Medicines & Healthcare Products Regulatory Agency	117778
NZ	Medicines and Medical Devices Safety Authority	3482, 9537
US	FDA, National Drug Code	0015-3404, 61269-410